Kairos Pharma has entered into binding terms to acquire CL-273, an investigational, reversible, wild-type-sparing pan‑EGFR small‑molecule inhibitor, from Celyn Therapeutics.  CL-273 was discovered using a proprietary AI-driven drug discovery platform. It targets the resistant mutations that develop when using EGFR tyrosine kinase inhibitors, thereby reversing resistance.   It is specifically engineered for EGFR‑mutant non-small lung cancer […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!